Abstract
Palmar-plantar psoriasis presents with erythematous, thick, scaly plaques on the palms and soles, which cause significant physical distress and occupational disability to patients affected. Mild cases of palmar-plantar psoriasis may be treated with high-potency topical corticosteroids. Severe cases may be treated with systemic therapies such as retinoids, methotrexate, cyclosporine, apremilast, ustekinumab, secukinumab, and ixekizumab. TNF inhibitors may paradoxically induce palmar-plantar psoriasis and should be avoided.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486–9. https://doi.org/10.1111/ced.12805.
Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024–31. https://doi.org/10.1016/j.jaad.2008.11.910.
Janagond AB, Kanwar AJ, Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. J Eur Acad Dermatol Venereol. 2013;27(3):e384–9. https://doi.org/10.1111/jdv.12004.
Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271–5.
Ortiz NE, Nijhawan RI, Weinberg JM. Acitretin. Dermatol Ther. 2013;26(5):390–9. https://doi.org/10.1111/dth.12086.
Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat. 2013;24(3):179–87. https://doi.org/10.3109/09546634.2012.672710.
Bissonnette R, Poulin Y, Guenther L, Lynde CW, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25(12):1402–8. https://doi.org/10.1111/j.1468-3083.2011.03984.x.
Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80. https://doi.org/10.1016/j.jaad.2016.07.058.
Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686–92. https://doi.org/10.1111/jdv.14237.
Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670–5. https://doi.org/10.1111/jdv.12359.
Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76(2):334–41. https://doi.org/10.1016/j.jaad.2016.08.012.
Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–40. https://doi.org/10.1016/j.semarthrit.2010.04.003.
Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17(4):349–58. https://doi.org/10.1007/s40257-016-0191-7.
Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179–85. https://doi.org/10.1016/j.jaad.2011.05.038.
Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9(1):1–14.
Sheu JS, Divito SJ, Enamandram M, Merola JF. Dapsone therapy for pustular psoriasis: case series and review of the literature. Dermatology. 2016;232(1):97–101. https://doi.org/10.1159/000431171.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wu, K.K., Lee, M.P., Wu, J.J. (2019). 67-Year-Old with Thick Plaques on the Palms. In: Wu, J. (eds) Clinical Cases in Psoriasis. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-18772-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-18772-9_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-18771-2
Online ISBN: 978-3-030-18772-9
eBook Packages: MedicineMedicine (R0)